What Will Be the Best Weight Loss Drug Stock of 2030: Eli Lilly, or Novo Nordisk?

There's reason to believe that one of these two players will eventually win.While the market for anti-obesity medicines is characterized today by a fight between Novo Nordisk's (NVO -0.88%) drug Wegovy and Eli Lilly's (LLY -2.02%) drug Zepbound, that won't always be the case. Over the coming years, the competitive dynamics of the market for weight loss medicines will change, and the competition is going to heat up big-time.Still, one of the two leaders of today's market is likely to be in the top position b ...